UniProt Q7L7X3 · PDB · AlphaFold · Substrate: MBP · Clone: aa1-314
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ripretinib | 83.4% | 16.6% | 92.95 | 0.674 |
| 2 | Pazopanib | 79.6% | 20.4% | 97.49 | 0.672 |
| 3 | Ponatinib | 78.6% | 21.4% | 78.23 | 0.534 |
| 4 | Abemaciclib | 78.5% | 21.5% | 91.48 | 0.563 |
| 5 | Brigatinib | 74.0% | 26.0% | 82.96 | 0.513 |
| 6 | Pacritinib | 67.7% | 32.3% | 88.64 | 0.452 |
| 7 | Defactinib | 63.7% | 36.3% | 92.68 | 0.450 |
| 8 | Crizotinib | 60.4% | 39.6% | 91.39 | 0.581 |
| 9 | Pemigatinib | 57.7% | 42.3% | 98.23 | 0.718 |
| 10 | Infigratinib | 54.7% | 45.3% | 98.24 | 0.710 |
| 11 | Midostaurin | 40.0% | 60.0% | 78.64 | 0.500 |
| 12 | Gilteritinib | 34.8% | 65.2% | 88.97 | 0.506 |
| 13 | Pexidartinib | 27.6% | 72.4% | 99.49 | 0.631 |
| 14 | Osimertinib | 26.8% | 73.2% | 97.24 | 0.733 |
| 15 | Bosutinib | 26.7% | 73.3% | 87.22 | 0.555 |
| 16 | Nilotinib | 24.7% | 75.3% | 96.49 | 0.765 |
| 17 | Palbociclib | 23.8% | 76.2% | 98.75 | 0.673 |
| 18 | Ceritinib | 22.8% | 77.2% | 95.44 | 0.618 |
| 19 | Dabrafenib | 21.6% | 78.4% | 94.74 | 0.633 |
| 20 | Apatinib | 21.4% | 78.6% | 97.73 | 0.704 |
Paralog block
TAOK1, TAOK2_TAO1, TAOK3_JIK
EMT expression
- Mesenchymal log2(TPM+1): 3.97
- Epithelial log2(TPM+1): 3.57
- Fold change: 0.40
- Status: No significant change
Selectivity landscape vs inhibition on TAOK1
Each point is one of the 92 approved drugs; color = inhibition % on TAOK1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…